Podcast
Questions and Answers
Selective ______, aprepitant and fosaprepitant (a prodrug of aprepitant), are now available for use as an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy. A newer NK1 receptor antagonist netupitant is now available as a mixed-dose combination with palonosetron (a 5HT3 antagonist) known as NEPA for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and highly emetogenic cisplatin-based chemotherapy. They appear to be well tolerated, but ______ are inhibitors, and sometimes inducers, of cytochrome P450 (CYP3A4) and inducers of CYP2C9. Therefore, potential drug interactions with chemotherapeutic agents and other concomitantly administered agents, for example, warfarin, may occur.
Selective ______, aprepitant and fosaprepitant (a prodrug of aprepitant), are now available for use as an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy. A newer NK1 receptor antagonist netupitant is now available as a mixed-dose combination with palonosetron (a 5HT3 antagonist) known as NEPA for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and highly emetogenic cisplatin-based chemotherapy. They appear to be well tolerated, but ______ are inhibitors, and sometimes inducers, of cytochrome P450 (CYP3A4) and inducers of CYP2C9. Therefore, potential drug interactions with chemotherapeutic agents and other concomitantly administered agents, for example, warfarin, may occur.
NK1 receptor antagonists
Selective ______, aprepitant and fosaprepitant (a prodrug of aprepitant), are now available for use as an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy. A newer NK1 receptor antagonist netupitant is now available as a mixed-dose combination with palonosetron (a 5HT3 antagonist) known as NEPA for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and highly emetogenic cisplatin-based chemotherapy. They appear to be well tolerated, but ______ are inhibitors, and sometimes inducers, of cytochrome P450 (CYP3A4) and inducers of CYP2C9. Therefore, potential drug interactions with chemotherapeutic agents and other concomitantly administered agents, for example, warfarin, may occur.
Selective ______, aprepitant and fosaprepitant (a prodrug of aprepitant), are now available for use as an adjunct to dexamethasone and a 5HT3 antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy. A newer NK1 receptor antagonist netupitant is now available as a mixed-dose combination with palonosetron (a 5HT3 antagonist) known as NEPA for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and highly emetogenic cisplatin-based chemotherapy. They appear to be well tolerated, but ______ are inhibitors, and sometimes inducers, of cytochrome P450 (CYP3A4) and inducers of CYP2C9. Therefore, potential drug interactions with chemotherapeutic agents and other concomitantly administered agents, for example, warfarin, may occur.
NK1 receptor antagonists
